Bausch & Lomb sale

Bausch & Lomb, the eye care company, has agreed to be sold to the Canadian healthcare company Valeant Pharmaceuticals for about $US8.7 billion ($9 billion). Valeant will pay $US4.5 billion to the investor group that owns B&L, led by private equity firm Warburg Pincus. It will also spend about $US4.2 billion to repay B&L's debt.

Bausch & Lomb, the eye care company, has agreed to be sold to the Canadian healthcare company Valeant Pharmaceuticals for about $US8.7 billion ($9 billion). Valeant will pay $US4.5 billion to the investor group that owns B&L, led by private equity firm Warburg Pincus. It will also spend about $US4.2 billion to repay B&L's debt.

Want access to our latest research and new buy ideas?

Start a free 15 day trial and gain access to our research, recommendations and market-beating model portfolios.

Sign up for free

Join the Conversation...

There are comments posted so far.

If you'd like to join this conversation, please login or sign up here

Related Articles